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Abstract 
Background: The prevalence and clinical significances of KRAS, GNAS, and RNF43 mutations in patients with pancre‑
atic intraductal papillary mucinous neoplasm (IPMN) remain elusive. To evaluate the incidence of the gene mutations 
and clinicopathologic differences between KRAS and GNAS mutations in pancreatic cystic lesions, we performed a 
meta‑analysis of published 33 KRAS, 11 GNAS, and 4 RNF43 studies including 1253, 835, and 143 cases, respectively.
Methods: We pooled the results of relevant studies identified using the PubMed and EMBASE databases. The effect 
sizes of outcome parameters were computed by the prevalence rate, weighted mean difference, or odds ratio (OR) 
using a random‑effects model.
Results: The pooled prevalence of KRAS, GNAS, and RNF43 mutations in IPMN was 61, 56, and 23 %, respectively. The 
KRAS (OR 7.4 and 71.2) and GNAS (OR 30.2 and 15.3) mutations were more frequently found in IPMNs than in muci‑
nous cystic neoplasms and in serous cystadenomas, respectively. Of the microscopic subtypes of IPMN, KRAS and 
GNAS were frequently mutated in gastric type (OR 2.7, P < 0.001) and intestinal type (OR 3.0, P < 0.001), respectively. 
KRAS mutation was infrequently found in high‑grade dysplasia lesions of IPMN (OR 0.6, P = 0.032). GNAS mutation was 
associated with male (OR 1.9, P = 0.012).
Conclusions: This meta‑analysis supports that KRAS and GNAS mutations could be diagnostic markers for IPMN. In 
addition, the frequencies of KRAS and GNAS mutations in IPMNs are highly variable according to the microscopic duct 
subtypes, reflecting their independent roles in the IPMN‑adenocarcinoma sequence.
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Background
Intraductal papillary mucinous neoplasm (IPMN) of the 
pancreas is a mucin-producing and cystic tumour grow-
ing inside the pancreatic duct and forming papillary pro-
jections (Klöppel et al. 2014; Klöppel and Kosmahl 2001). 
IPMN is considered as a precursor of pancreatic adeno-
carcinoma and comprised of about 16–24  % of cystic 
pancreatic lesions (Klöppel et al. 2014; Klöppel and Kos-
mahl 2001). IPMN forms a multilocular cystic lesion and 
is difficult to distinguish from mucinous cystic neoplasm 
(MCN) (Klöppel et al. 2014; Klöppel and Kosmahl 2001).
Recently, genetic studies of IPMN lead to discover 
mutations of new genes, including GNAS, and RNF43 
(Macgregor-Das and Iacobuzio-Donahue 2013; Reid et al. 
2014). In addition to the previously known genetic altera-
tion such as KRAS, these gene mutations open a new 
viewpoint in the field of the molecular pathogenesis of 
IPMN. Nevertheless, the frequencies and clinicopatho-
logic significances of KRAS, GNAS, and RNF43 have not 
been clearly delineated. Activating GNAS mutation at 
codon 201 has been identified in IPMNs of the pancreas, 
which runs from 36 to 79 % (Amato et al. 2014; Hosoda 
et al. 2015; Ideno et al. 2015; Kanda et al. 2013; Kuboki 
et  al. 2015; Lee et  al. 2014; Siddiqui et  al. 2013; Singhi 
et al. 2014; Takano et al. 2014; Tan et al. 2015; Wu et al. 
2011b). Moreover, the wide extreme diversity of KRAS 
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mutation in IPMN patients, ranged from 13 to 100 %, has 
been observed (Amato et al. 2014; Chadwick et al. 2009; 
Chang et al. 2014; Fritz et al. 2009; Furukawa et al. 2005; 
Hosoda et  al. 2015; Ideno et  al. 2015; Jang et  al. 2009; 
Kaino et al. 1999; Kitago et al. 2004; Kobayashi et al. 2008; 
Kondo et  al. 1997; Kuboki et  al. 2015; Lee et  al. 2014; 
Lubezky et al. 2011; Mizuno et al. 2010; Mohri et al. 2012; 
Mueller et  al. 2003; Mulligan et  al. 1999; Nakata et  al. 
2002; Paal et al. 1999; Raimondo et al. 2002; Schönleben 
et al. 2008; Sessa et al. 1994; Siddiqui et al. 2013; Singhi 
et al. 2014; Tada et al. 1991; Takano et al. 2014; Tan et al. 
2015; Uemura et  al. 2003; Wada et  al. 2004; Wu et  al. 
2011b; Yoshizawa et  al. 2002). The frequency of RNF43 
mutation was ranged from 14 to 75 % (Amato et al. 2014; 
Sakamoto et al. 2015; Tan et al. 2015; Wu et al. 2011a).
Therefore, in this meta-analysis, we aimed to know 
the exact prevalence of KRAS, GNAS, and RNF43 muta-
tions in IPMN patients, and the difference between the 
frequency of these mutant genes in pancreatic cystic 
lesions. In addition, we investigated whether KRAS and 
GNAS mutations have clinicopathologic significances in 
patients with IPMN.
Methods
Data collection and selection criteria
We searched PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and EMBASE (www.embase.com) using the 
keywords “KRAS”, “GNAS”, “RNF43”, “pancreas” and 
“intraductal papillary mucinous neoplasm”. We also 
manually searched the reference lists of the identified 
articles. Duplicate data or overlapping articles were 
excluded by examining the authors’ names and affilia-
tions. Original articles reporting cases of KRAS, GNAS, 
and RNF43 mutations published before June 2015 were 
included. When multiple articles were published by the 
same authors or institutions, the most recent or single 
informative article was selected. Articles lacking clinico-
pathologic data for meta-analysis, review articles without 
original data, conference abstracts, case reports, and arti-
cles that dealt with cell line or animal were excluded. In 
addition, immunohistochemical studies of RAS mutation 
were also excluded. There were no geographic or lan-
guage restrictions. The selection process of the articles is 
shown in Fig. 1.
Data pooling and statistics
Meta-analysis was performed as previously described 
(Lee et al. 2011). Briefly, effect sizes for each study were 
calculated by prevalence rate or odds ratio (OR) and the 
corresponding 95  % confidence interval (CI) using the 
Mantel–Haenszel method. The prevalence rate, weighted 
mean difference (WMD), or OR was combined using a 
random-effects model (DerSimonian–Laird method). 
Statistical heterogeneity among studies was evaluated 
using the Cochrane Q test and I2 statistics. The I2 sta-
tistic refers to the percentage of variation across studies 
that is due to heterogeneity rather than chance and does 
not inherently depend on the number of studies consid-
ered [I2 = 100 % × (Q-df)/Q]. We clarified the cutoff of 
I2 statistics for assignment of low (<25 %), moderate (25–
50  %), and high (>50  %) heterogeneities. If I2 value was 
more than 50  %, subgroup analysis was done. Sensitiv-
ity analyses were performed to examine the influence of 
each study on the pooled prevalence rate, WMD, or OR 
by serially omitting an individual study and pooling the 
remaining studies. Publication bias was examined by fun-
nel plots and Egger’s tests for the degree of asymmetry. 
Publication bias was assumed to be present if the P value 
was less than 0.1. The pooled analysis was performed 
using Comprehensive Meta-analysis Software version 2.0 
(Biostat, Englewood, NJ, USA).
Results
Thirty-three and eleven studies reported the frequencies 
of KRAS and GNAS mutations between 1253 and 835 
IPMN patients, respectively (Tables  1, 2) (Amato et  al. 
2014; Chadwick et al. 2009; Chang et al. 2014; Fritz et al. 
2009; Furukawa et  al. 2005; Hosoda et  al. 2015; Ideno 
et al. 2015; Jang et al. 2009; Kaino et al. 1999; Kanda et al. 
2013; Kitago et  al. 2004; Kobayashi et  al. 2008; Kondo 
et  al. 1997; Kuboki et  al. 2015; Lee et  al. 2014; Lubezky 
et al. 2011; Mizuno et al. 2010; Mohri et al. 2012; Muel-
ler et  al. 2003; Mulligan et  al.  1999;  Nakata et  al. 2002; 
Paal et al. 1999; Raimondo et al. 2002; Schönleben et al. 
2008; Sessa et al. 1994; Siddiqui et al. 2013; Singhi et al. 
2014; Tada et al. 1991; Takano et al. 2014; Tan et al. 2015; 
Uemura et  al. 2003; Wada et  al. 2004; Wu et  al. 2011b; 
Yoshizawa et  al. 2002). On pooled analysis, KRAS and 
GNAS mutations were 60.9  % (95  % CI 54.3–67.1) and 
55.8  % (95  % CI 48.5–62.8) in IPMN patients (Table  3). 
The KRAS and GNAS mutations did not differ according 
to the ethnicity, detection methods, and specimen type 
(Table 3). Additionally, eight studies presented the cases 
having both KRAS and GNAS mutations (Amato et  al. 
2014; Hosoda et  al. 2015; Kuboki et  al. 2015; Lee et  al. 
2014; Siddiqui et  al. 2013; Singhi et  al. 2014; Tan et  al. 
2015; Wu et al. 2011b). On pooled analysis, 33.5 % (95 % 
CI 26.2–41.6) of IPMN patients harboured both KRAS 
and GNAS mutations. On the other hand, four studies 
(Amato et al. 2014; Sakamoto et al. 2015; Tan et al. 2015; 
Wu et  al. 2011a) described the prevalence of RNF43 
mutation among 143 IPMN patients (Additional file  1: 
Table S1). On pooled analysis, the frequency of RNF43 
mutation was 22.9 % (95 % CI 10.8–42.4).  
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Other cystic lesions
Seven (Hosoda et  al. 2015; Lee et  al. 2014; Schönleben 
et  al. 2008; Singhi et  al. 2014; Uemura et  al. 2003; Wu 
et  al. 2011b; Yoshizawa et  al. 2002) and four (Hosoda 
et al. 2015; Lee et al. 2014; Siddiqui et al. 2013; Wu et al. 
2011b) studies presented KRAS and GNAS mutations 
between IPMN and MCN patients. KRAS mutation 
was found in 239 (69 %) of 345 IPMN and 14 (21 %) of 
67 MCN patients. GNAS mutation was detected in 168 
(58 %) of 292 IPMN and in none of 57 MCN. The over-
all ORs for KRAS and GNAS mutations in IPMN patients 
were 7.444 (95 % CI 3.850–14.392; P < 0.001, Q = 4.540, 
I2 = 0.000) and 30.194 (95 % CI 7.143–127.622; P < 0.001, 
Q = 0.787, I2 = 0.000), compared with those mutations 
in MCN, respectively (Fig. 2).
Four (Hosoda et al. 2015; Lee et al. 2014; Singhi et al. 
2014; Wu et  al. 2011b) and five (Hosoda et  al. 2015; 
Kanda et al. 2013; Lee et al. 2014; Singhi et al. 2014; Wu 
et  al. 2011b) studies addressed KRAS and GNAS muta-
tions between IPMN and serous cystadenoma (SCA) 
patients, respectively. KRAS mutation was found in 210 
(72 %) of 292 IPMN and none (0 %) of 83 SCA patients. 
GNAS mutation was detected in 217 (59 %) of 370 IPMN 
patients and 2 (2 %) of 82 SCA patients. The overall ORs 
for KRAS and GNAS mutation in IPMN patients were 
71.240 (95  % CI 16.856–301.086; P  <  0.001, Q =  1.810, 
I2 = 0.000) and 15.297 (95 % CI 4.544–51.498; P < 0.001, 
Q = 4.525, I2 = 11.611), respectively.
Age and sex
The incidence of KRAS and GNAS mutations in patients 
with IPMN according to the patient’s sex was compared 
in eleven (Fritz et  al. 2009; Hosoda et  al. 2015; Kob-
ayashi et al. 2008; Kondo et al. 1997; Mulligan et al. 1999; 
Schönleben et  al. 2008; Singhi et  al. 2014; Tada et  al. 
1991; Uemura et  al. 2003; Wada et  al. 2004; Wu et  al. 
2011b) and six (Hosoda et  al. 2015; Ideno et  al. 2015; 
Kanda et al. 2013; Singhi et al. 2014; Takano et al. 2014; 
Wu et  al. 2011b) studies, respectively. KRAS mutation 
was detected in 162 (69 %) of 236 male patients and 120 
(69  %) of 173 female patients with IPMN. GNAS muta-
tion was detected in 198 (63 %) of 314 male patients and 
110 (48 %) of 229 female patients with IPMN. The over-
all ORs for KRAS and GNAS mutations in male patients 
with IPMN were 1.065 (95 % CI 0.680–1.668; P = 0.782, 
Q = 7.216, I2 = 0.000) and 1.946 (95 % CI 1.156–3.278; 
P = 0.012, Q = 9.885, I2 = 49.419), respectively (Fig. 3).
Five (Fritz et al. 2009; Kobayashi et al. 2008; Schönleben 
et al. 2008; Singhi et al. 2014; Wada et al. 2004) and three 
(Kanda et  al. 2013; Singhi et  al. 2014; Wu et  al. 2011b) 
studies presented mean age with standard deviation (SD) 
or p value according to KRAS and GNAS mutations, 
respectively. The mean age of IPMN patients with KRAS 
mutation ranged from 63.67 to 70.15 years, whereas the 
mean age of those with wild-type KRAS ranged from 
64.3 to 68.58  years. The mean age of IPMN patients 
with GNAS mutation ranged from 62.14 to 69.54  years, 
138 papers were retrieved for the key 
words and their abstracts were 
reviewed
70 full texts were reviewed
 36 studies were included in this meta-analysis 
 68 articles were excluded, due to:  
(1) 22 papers were review  articles 
(2) 7 papers were case report 
(3) 10 papers were animal study 
(4) 29 articles were obviously irrelevant or not 
associated with GNAS, KRAS, or RNF43 
mutations of intraductal papillary mucinous 
neoplasm of pancreas 
34 articles were excluded due to: 
  (1) 23 papers were duplicated publications 
  (2) 7 papers did not provide sufficient data 
  (3) 4 papers were immunohistochemical studies 
Fig. 1 Flow diagram of article selection for this meta‑analysis
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whereas the mean age of those with wild-type GNAS 
ranged from 59 to 70.09  years. No associations were 
found between mean age and KRAS (WMD  =  0.140; 
95  % CI −0.194 to 0.475; P  =  0.410, Q  =  2.940, 
I2 = 0.000) or GNAS (WMD = 0.099; 95 % CI −0.156 to 
0.354; P = 0.448, Q = 1.838, I2 = 0.000) mutations.
Location and tumour size
The incidence of KRAS or GNAS mutation in patients 
with IPMN according to the location (head versus body 
or tail) was compared in eight (Hosoda et  al. 2015; 
Kobayashi et al. 2008; Kondo et al. 1997; Schönleben et al. 
2008; Singhi et al. 2014; Uemura et al. 2003; Wada et al. 
2004; Wu et al. 2011b) and six (Hosoda et al. 2015; Ideno 
et al. 2015; Kanda et al. 2013; Singhi et al. 2014; Takano 
et al. 2014; Wu et al. 2011b) studies, respectively. KRAS 
mutation was detected in 154 (67 %) of 229 patients with 
IPMN arising in the pancreatic head and 97 (75 %) of 130 
patients in the body or tail. GNAS mutation was detected 
in 168 (58  %) of 288 patients with IPMN arising in the 
pancreatic head and 125 (56  %) of 224 patients in the 
body or tail. There were no associations between KRAS 
Table 1 Characteristics of individual studies of KRAS mutation in patients with intraductal papillary mucinous neoplasm
 ASH allele-specific oligonucleotide hybridization, PCR polymerase chain reaction, HRM high-resolution melt-curve analysis, SSCP single strand conformation 
polymorphism, PHFA preferential homoduplex formation assay, RFLP restriction fragment length polymorphism 
Study Country Ethnicity Detection method Specimen KRAS mutation (%)
Amato E Italy Caucasian Sequencing Tissue 24/48 (50.0)
Chadwick B USA Caucasian Sequencing Tissue 37/52 (71.2)
Chang X China Asian Sequencing Tissue 9/16 (56.3)
Fritz S USA Caucasian Sequencing Tissue 8/20 (40.0)
Furukawa T Japan Asian ASH, sequencing Tissue 5/6 (83.3)
Hosoda W Japan Asian real‑time PCR, sequencing Tissue 59/91 (64.8)
Ideno N Japan Asian HRM, sequencing Tissue 75/95 (78.9)
Jang JY Korea Asian Sequencing Tissue 13/37 (35.1)
Kaino M Japan Asian SSCP, sequencing Pancreatic juice 12/12 (100.0)
Kitago M Japan Asian Sequencing Tissue 16/20 (80.0)
Kobayashi N Japan Asian PCR/PHFA Pancreatic juice 13/22 (59.1)
Kondo H Japan Asian SSCP, sequencing Pancreatic juice 12/13 (92.3)
Kuboki Y Japan Asian Sequencing Tissue 96/172 (55.8)
Lee LS USA Caucasian Sequencing Tissue 9/19 (47.4)
Lubezky N Israel Caucasian Sequencing Tissue 9/27 (33.3)
Mizuno O Japan Asian Semiquantitative PCR Pancreatic juice 43/53 (81.1)
Mohri D Japan Asian Sequencing Tissue 14/25 (56.0)
Muller J Germany Caucasian PCR–RFLP Tissue 4/13 (30.8)
Mulligan NJ USA Caucasian PCR Tissue 5/7 (71.4)
Nakata B Japan Asian SSCP, sequencing Tissue 19/26 (73.1)
Paal E USA Caucasian Sequencing Tissue 2/15 (13.3)
Raimondo M USA Caucasian SSCP, sequencing Tissue 29/40 (72.5)
Schönleben F USA Caucasian Sequencing Tissue 17/36 (47.2)
Sessa F Italy Caucasian SSCP, sequencing Tissue 8/26 (30.8)
Siddiqui AA USA Caucasian Quantitative PCR Cyst fluid 6/9 (66.7)
Singhi AD USA Caucasian Sequencing Cyst fluid 35/50 (70.0)
Tada M Japan Asian Sequencing Tissue 3/5 (60.0)
Takano S Japan Asian Sequencing Tissue 6/6 (100.0)
Pancreatic juice 32/50 (64.0)
Tan MC USA Caucasian Sequencing Tissue 27/38 (71.1)
Uemura K Japan Asian Sequencing Tissue 8/10 (80.0)
Wada K Japan Asian Sequencing Tissue 15/23 (65.2)
Wu J USA Caucasian PCR/ligation Tissue 39/49 (79.6)
Cyst fluid 68/83 (81.9)
Yoshizawa K Japan Asian Sequencing Tissue 4/7 (57.1)
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or GNAS mutation and tumour location (OR 0.836, 95 % 
CI 0.477–1.465, P  =  0.532, Q  =  7.624, I2  =  8.182 and 
OR 1.133, 95  % CI 0.785–1.634, P =  0.505, Q =  2.131, 
I2 = 0.000, respectively).
Four (Kanda et al. 2013; Kuboki et al. 2015; Singhi et al. 
2014; Wu et al. 2011b) and three (Kuboki et al. 2015; Sin-
ghi et al. 2014; Wada et al. 2004) studies presented mean 
tumour size with SD or p value according to KRAS or 
GNAS mutation, respectively. The average tumour size of 
IPMN patients with KRAS mutations ranged from 2.4 to 
2.9 cm, whereas the mean size of IPMNs with wild-type 
KRAS ranged from 2.51 to 2.86  cm. The mean tumour 
size of IPMNs with GNAS mutation ranged from 1.234 
to 3.859  cm, whereas the average size of IPMNs with 
wild-type GNAS ranged from 1.134 to 3.66 cm. No rela-
tionship was found between the average tumour size 
and KRAS or GNAS mutation (WMD = 0.000, 95 % CI 
−0.258 to 0.258, P  >  0.999, Q  =  0.860, I2  =  0.000 and 
WMD  =  0.086, 95  % CI −0.108 to 0.280, P  =  0.384, 
Q = 0.315, I2 = 0.000, respectively).
Macroscopic and microscopic duct types of IPMNs
Nine (Fritz et  al. 2009; Hosoda et  al. 2015; Kaino et  al. 
1999; Kobayashi et  al. 2008; Kondo et  al. 1997; Kuboki 
Table 2 Characteristics of individual studies of GNAS mutation in patients with IPMN
PCR polymerase chain reaction, HRM high-resolution melt-curve analysis
Study Country Ethnicity Detection method Specimen GNAS mutation (%)
Amato E Italy Caucasian Sequencing Tissue 38/48 (79.2)
Hosada W Japan Asian Real‑time PCR, sequencing Tissue 55/91 (60.4)
Ideno N Japan Asian HRM, sequencing Tissue 65/110 (59.1)
Kanda M USA Caucasian HRM, pyrosequencing Pancreatic juice 49/78 (62.8)
Kuboki Y Japan Asian Sequencing Tissue 82/172 (47.7)
Lee LS USA Caucasian Sequencing Tissue 8/19 (42.1)
Siddiqui AA USA Caucasian Quantitative PCR Cyst fluid 4/9 (44.4)
Singhi AD USA Caucasian Sequencing Cyst fluid 18/50 (36.0)
Takano S Japan Asian Sequencing Tissue 4/6 (66.7)
Pancreatic juice 34/82 (41.5)
Tan MC USA Caucasian Sequencing Tissue 23/38 (60.5)
Wu J USA Caucasian PCR/ligation Tissue 36/49 (73.5)
Cyst fluid 51/83 (61.4)
Table 3 Prevalence of KRAS and GNAS mutations in patients with  IPMN according to the ethnicity, mutation detection, 
and specimen type
CI confidence interval
a Two studies were performed in both tissue and cyst fluid
Category KRAS mutation GNAS mutation
No. of studies No. of cases Prevalence (%) 
(95 % CI)
P value No. of studies No. of cases Prevalence (%) 
(95 % CI)
P value
Overall 33 1253 60.9 (54.3–67.1) 11 835 55.8 (48.5–62.8)
Ethnicity 0.106 0.429
 Caucasian 15 532 55.1 (45.2–64.7) 7 374 58.4 (48.8–67.4)
 Asian 18 721 66.0 (56.9–74.0) 4 461 52.6 (41.8–63.1)
Detection method 0.207 0.552
 Sequencing 27 1017 59.0 (52.1–65.6) 9 694 54.9 (47.0–62.5)
 Non‑sequencing 6 236 69.0 (54.6–80.4) 2 141 60.9 (42.3–76.9)
Specimen typea 0.095 0.147
 Tissue 27 929 58.9 (51.3–66.1) 8 533 61.0 (52.0–69.4)
 Cyst fluid or pancre‑
atic juice
8 324 71.4 (58.4–81.7) 5 302 50.3 (39.1–61.5)
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et  al. 2015; Lee et  al. 2014; Singhi et  al. 2014; Wu et  al. 
2011b) and seven (Hosoda et al. 2015; Ideno et al. 2015; 
Kuboki et  al. 2015; Lee et  al. 2014; Singhi et  al. 2014; 
Takano et  al. 2014; Wu et  al. 2011b) studies addressed 
KRAS and GNAS mutations in IPMN patients, accord-
ing to the macroscopic duct type, respectively (Table 4). 
KRAS mutation was found in 97 (61 %) of 160 main duct 
type, 191 (70 %) of 272 branch duct type, and 58 (62 %) 
of 94 mixed duct type. GNAS mutation was found in 105 
(56 %) of 187 main duct type, 160 (49 %) of 327 branch 
duct type, and 45 (51  %) of 89 mixed duct type. KRAS 
and GNAS mutations were not significantly related 
to main (OR 0.614, 95  % CI 0.342–1.102, P  =  0.102, 
Q = 10.686, I2 = 34.496 and OR 1.346, 95 % CI 0.934–
1.939, P  =  0.681, Q  =  3.972, I2  =  0.000, respectively) 
and branch duct types (OR 1.662, 95 % CI 0.859–3.216, 
P  =  0.132, Q  =  13.149, I 2  =  46.764 and OR 0.815, 
95 % CI 0.585–1.136, P = 0.577, Q = 4.743, I2 = 0.000, 
respectively).
Ten (Amato et  al. 2014; Chadwick et  al. 2009; Fritz 
et  al. 2009; Hosoda et  al. 2015; Jang et  al. 2009; Kuboki 
et  al. 2015; Mohri et  al. 2012; Singhi et  al. 2014; Tan 
et al. 2015; Wu et al. 2011b) and six (Amato et al. 2014; 
Hosoda et al. 2015; Kuboki et al. 2015; Singhi et al. 2014; 
Tan et al. 2015; Wu et al. 2011b) studies described KRAS 
and GNAS mutations in IPMN patients, according to 
the microscopic duct type, respectively (Table 5). KRAS 
mutation was detected in 228 (73 %) of 314 gastric type, 
47 (72 %) of 65 pancreatobiliary duct type, 99 (44 %) of 
227 intestinal type, and 5 (29  %) of 17 oncocytic type. 
KRAS mutation was significantly found in gastric type 
(OR 2.748; 95  % CI 1.888–4.000; P  <  0.001, Q =  5.679, 
I2 = 0.000) with high frequency (Fig. 4), compared to its 
frequency in intestinal type (OR 0.311; 95  % CI 0.206–
0.471; P < 0.001, Q = 10.036, I2 = 10.324).
On the other hand, GNAS mutation was detected in 
122 (74 %) of 164 intestinal type, 137 (53 %) of 260 gas-
tric type, 12 (24 %) of 49 pancreatobiliary duct type, and 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Hosoda W 31.932 1.815 561.837 2.367 0.018
Lee LS 15.522 0.794 303.254 1.808 0.071
Singhi AD 18.785 1.064 331.575 2.002 0.045
Wu J 82.692 4.896 1396.565 3.061 0.002
30.194 7.143 127.622 4.633 0.000
0.01 0.1 1 10 100
MCN IPMN
Fig. 2 Odds ratios with corresponding 95 % confidence intervals of individual studies and pooled data for the association of GNAS mutation with 
intraductal papillary mucinous neoplasm (IPMN), compared with mucinous cystic neoplasm (MCN). Forest plot demonstrates the effect sizes and 
95 % CIs for each study and overall
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Hosoda W 2.000 0.839 4.769 1.563 0.118
Ideno N 3.484 1.517 8.003 2.943 0.003
Kanda M 1.029 0.410 2.578 0.060 0.952
Singhi AD 7.308 1.755 30.423 2.733 0.006
Takano S 0.905 0.372 2.198 -0.221 0.825
Wu J 1.939 0.935 4.020 1.779 0.075
1.946 1.156 3.278 2.505 0.012
0.01 0.1 1 10 100
Female Male
Fig. 3 Forest plot of odds ratios with corresponding 95 % confidence intervals for the association of GNAS mutation of IPMN with male patients
Page 7 of 12Lee et al. SpringerPlus  (2016) 5:1172 
2 (15 %) of 13 oncocytic type. GNAS mutation was sig-
nificantly found in intestinal type with high frequency 
(OR 2.955; 95  % CI 1.771–4.929; P  <  0.001, Q =  5.537, 
I2 =  9.694) (Fig.  5) and was present in pancreatobiliary 
and oncocytic types with low frequency (OR 0.220; 95 % 
CI 0.108–0.450; P  <  0.001, Q  =  3.009, I2  =  0.000 and 
OR 0.128; 95  % CI 0.031–0.537; P =  0.005, Q =  0.033, 
I2 = 0.000, respectively).
However, KRAS mutation was not significantly asso-
ciated with pancreatobiliary and oncocytic types, 
respectively (OR 1.604, 95 % CI 0.873–2.947, P = 0.128, 
Q  =  4.971, I2  =  0.000 and OR 0.415; 95  % CI 0.129–
1.336; P  =  0.140, Q  =  3.643, I2  =  0.000, respectively). 
GNAS mutation was not significantly associated with 
gastric type (OR 0.845, 95 % CI 0.560–1.275, P = 0.422, 
Q = 3.189, I2 = 0.000, respectively).
Histologic grade and presence of adenocarcinoma
Nine (Amato et al. 2014; Chadwick et al. 2009; Fritz et al. 
2009; Hosoda et  al. 2015; Kuboki et  al. 2015; Lubezky 
et al. 2011; Schönleben et al. 2008; Singhi et al. 2014; Wu 
et al. 2011b) and seven (Amato et al. 2014; Hosoda et al. 
2015; Ideno et al. 2015; Kanda et al. 2013; Kuboki et al. 
2015; Singhi et  al. 2014; Wu et  al. 2011b) studies pre-
sented KRAS and GNAS mutations of IPMN patients, 
according to the histologic grades. KRAS mutation was 
detected in 132 (58  %) of 227 high grade, 95 (70  %) of 
136 intermediate grade, and 129 (63 %) of 205 low grade. 
KRAS mutation was detected in high grade dysplasia 
with lower frequency (OR 0.626; 95  % CI 0.408–0.961; 
P = 0.032, Q = 7.797, I2 = 10.219) (Fig. 6).
However, the prevalence of KRAS mutation in low 
and intermediate grades was not statistically significant 
Table 4 Characteristics of individual studies of KRAS and GNAS mutations in patients with IPMN according to the macro-
scopic duct types
Study KRAS mutation (mutation/total) (%) GNAS mutation (mutation/total) (%)
Main duct Branch duct Mixed duct Main duct Branch duct Mixed duct
Fritz S 2/2 (100) 0/2 (0) 6/16 (38)
Hosada W 25/41 (61) 34/50 (68) 26/41 (63) 29/50 (58)
Ideno N 2/6 (33) 22/45 (49) 7/11 (64)
Kaino M 5/5 (100) 7/7 (100)
Kobayashi N 1/2 (50) 12/20 (60)
Kondo H 3/3 (100) 9/10 (90)
Kuboki Y 29/50 (58) 42/81 (52) 25/41 (61) 27/50 (54) 41/81 (51) 15/41 (37)
Lee LS 3/9 (33) 6/10 (60) 4/9 (44) 4/10 (40)
Singhi AD 6/13 (46) 23/28 (82) 6/9 (67) 4/13 (31) 11/28 (39) 3/9 (33)
Takano S 18/33 (55) 16/49 (33)
Wu J 23/35 (66) 58/64 (91) 21/28 (75) 24/35 (69) 38/64 (59) 20/28 (71)
Table 5 Characteristics of individual studies of KRAS and GNAS mutations in patients with IPMN according to the micro-
scopic duct types
Study KRAS mutation (mutation/total) (%) GNAS mutation (mutation/total) (%)
Gastric Pancreato biliary Intestinal Oncocytic Gastric Pancreato biliary Intestinal Oncocytic
Amato E 5/6 (83) 3/3 (100) 14/36 (39) 2/3 (67) 6/6 (100) 1/3 (33) 30/36 (83) 1/3 (33)
Chadwick B 16/19 (84) 6/7 (86) 15/26 (58)
Fritz S 7/10 (70) 1/7 (14) 0/2 (0)
Hosada W 40/55 (73) 6/7 (86) 12/27 (44) 1/2 (50) 34/55 (62) 0/7 (0) 21/27 (74) 0/2 (0)
Jang JY 5/13 (38) 4/8 (50) 4/19 (21)
Kuboki Y 63/97 (65) 7/11 (64) 25/56 (45) 1/8 (13) 45/97 (46) 3/11 (27) 33/56 (59) 1/8 (13)
Mohri D 9/11 (82) 1/1 (100) 3/11 (27) 1/2 (50)
Singhi AD 30/40 (75) 3/5 (60) 2/5 (40) 13/40 (33) 0/5 (0) 5/5 (100)
Tan MC 8/10 (80) 10/16 (63) 17/27 (63) 5/10 (50) 5/16 (31) 20/27 (74)
Wu J 45/52 (87) 7/7 (100) 6/13 (46) 34/52 (65) 3/7 (43) 13/13 (100)
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(OR 1.521, 95 % CI 0.984–2.353, P = 0.059, Q = 1.929, 
I2 = 0.000, and OR 1.139, 95 % CI 0.657–1.976, P = 0.643, 
Q  =  8.326, I2  =  15.929, respectively). GNAS mutation 
was detected in 120 (61 %) of 198 high grade, 86 (67 %) of 
128 intermediate grade, and 119 (56 %) of 213 low grade. 
The frequency of GNAS mutation did not differ among 
high, intermediate, and low grades of IPMN patients 
(OR 0.769, 95 % CI 0.382–1.547, P = 0.461, Q = 15.126, 
I2 = 60.334; OR 1.273, 95 % CI 0.786–2.060, P = 0.326, 
Q  =  2.789, I2  =  0.000, and OR 0.938, 95  % CI 0.500–
1.761, P = 0.843, Q = 12.357, I2 = 51.445, respectively). 
The subgroup analysis revealed that the detection meth-
ods influenced the relationship between GNAS mutation 
and high grade dysplasia of IPMN (Additional file  2: 
Table S2).
Twenty-one (Amato et  al. 2014; Fritz et  al. 2009; 
Hosoda et  al. 2015; Ideno et  al. 2015; Jang et  al. 2009; 
Kondo et  al. 1997; Kuboki et  al. 2015; Lubezky et  al. 
2011; Mizuno et al. 2010; Mohri et al. 2012; Mueller et al. 
2003; Mulligan et al. 1999; Nakata et al. 2002; Raimondo 
et al. 2002; Schönleben et al. 2008; Sessa et al. 1994; Sin-
ghi et al. 2014; Uemura et al. 2003; Wada et al. 2004; Wu 
et al. 2011b; Yoshizawa et al. 2002) and six (Amato et al. 
2014; Hosoda et al. 2015; Ideno et al. 2015; Kuboki et al. 
2015; Singhi et al. 2014; Wu et al. 2011b) studies reported 
KRAS and GNAS mutations in IPMN patients, according 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Amato E 6.053 0.650 56.365 1.582 0.114
Chadwick B 3.048 0.735 12.640 1.535 0.125
Fritz S 18.667 1.563 222.926 2.313 0.021
Hosoda W 2.386 0.986 5.772 1.929 0.054
Jang JY 1.319 0.335 5.194 0.397 0.692
Kuboki Y 2.358 1.271 4.375 2.721 0.007
Mohri D 8.100 1.233 53.200 2.178 0.029
Singhi AD 3.000 0.717 12.553 1.504 0.132
Tan MC 2.370 0.447 12.571 1.014 0.311
Wu J 3.462 1.026 11.677 2.002 0.045
2.748 1.888 4.000 5.278 0.000
0.01 0.1 1 10 100
others gastric type
Fig. 4 Forest plot of odds ratios with corresponding 95 % confidence intervals for the association of KRAS mutation with gastric subtype of IPMN
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Amato E 2.500 0.566 11.051 1.208 0.227
Hosoda W 3.088 1.101 8.664 2.142 0.032
Kuboki Y 1.962 1.027 3.748 2.040 0.041
Singhi AD 26.481 1.367512.985 2.167 0.030
Tan MC 4.571 1.421 14.705 2.550 0.011
Wu J 16.200 0.918285.906 1.901 0.057
2.955 1.771 4.929 4.150 0.000
0.01 0.1 1 10 100
others intestinal type
Fig. 5 Forest plot of odds ratios with corresponding 95 % confidence intervals for the association of GNAS mutation with intestinal subtype of IPMN
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to the presence of associated pancreatic adenocarci-
noma. KRAS mutation was present in 190 (64 %) of 297 
IPMN patients with invasive adenocarcinoma, whereas 
388 (63  %) of 620 IPMNs without adenocarcinoma. 
GNAS mutation was present in 80 (51  %) of 157 IPMN 
patients with invasive adenocarcinoma, whereas 265 
(59  %) of 446 IPMNs without adenocarcinoma. No sig-
nificant associations were seen between KRAS and GNAS 
mutations and the presence of adenocarcinoma in IPMN 
patients (OR 1.342, 95  % CI 0.878–2.050, P  =  0.174, 
Q = 26.746, I2 = 25.222, and OR 0.548, 95 % CI 0.285–
1.053, P = 0.071, Q = 10.231, I2 = 51.131, respectively). 
The subgroup analyses disclosed that the ethnicity and 
detection methods of these mutations did not influence 
the relationship between GNAS mutation and IPMN-
associated adenocarcinoma (Additional file 2: Table S2).
Sensitivity analysis and publication bias
The sensitivity analyses showed that none of the stud-
ies affected the pooled prevalence rate, OR, or WMD 
with CIs, except the pooled analysis of GNAS mutation 
between the genders and of KRAS mutation between 
high grade and the other grades of IPMNs (Additional 
file 3: Fig. S1). Through the funnel plots and the Egger’s 
regression tests, the pooled results from KRAS muta-
tion between tumour locations within the pancreas, 
GNAS mutation between mean tumour size and between 
intermediate grade and the other grades, and KRAS and 
GNAS mutations between microscopic duct subtypes of 
IPMNs showed the possibility of publication bias. How-
ever, other pooled analyses showed no evidence of publi-
cation bias (Additional file 4: Table S3) (Additional file 5: 
Fig. S2).
Discussion
This pooled analysis using data from 1253, 835, and 143 
pancreatic IPMN patients revealed that overall KRAS, 
GNAS, and RNF43 mutations were detected in 61, 56, 
and 23  %, respectively. These gene mutation rates did 
not differ according to the ethnicity, detection meth-
ods, and specimen type. This meta-analysis showed that 
the frequencies of KRAS and GNAS mutations in IPMN 
patients were considerably variable among microscopic 
duct subtypes.
The most common preoperative challenge is to distin-
guish IPMN from other cystic lesions of the pancreas. 
There are three primary types of pancreatic cystic neo-
plasm: IPMN, MCN, and SCA (Wu et  al. 2011b). Most 
of the pancreatic adenocarcinomas develop from IPMNs, 
followed by MCNs. In contrast, SCAs do not give rise to 
invasive adenocarcinomas (Wu et al. 2011b). Until now, 
preoperative cystic fluid evaluation for CEA, amylase, 
DNA methylation, and microRNA expression remains 
suboptimal, partly because of their lack of disease speci-
ficity (Weinstein et al. 2004). Based on the high frequen-
cies and significant ORs of KRAS and GNAS mutations 
in IPMNs compared to the other cystic lesions, particu-
larly MCNs, the combined detection of KRAS and GNAS 
mutations from the cystic fluid would be highly valuable 
in the preoperative diagnosis of IPMNs.
This pooled analysis found that different mutational 
profile between KRAS and GNAS was significantly 
related to the microscopic subtypes of IPMNs, which are 
a determinant for the subtypes of invasive adenocarcino-
mas. Over 30 % of intestinal and pancreaticobiliary type 
IPMNs develop colloid and tubular type adenocarcino-
mas, respectively (Klöppel et al. 2014). In contrast, gastric 
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Amato E 0.348 0.106 1.147 -1.734 0.083
Chadwick B 1.320 0.347 5.018 0.407 0.684
Fritz S 0.333 0.027 4.186 -0.851 0.395
Hosoda W 1.185 0.501 2.806 0.386 0.699
Kuboki Y 0.565 0.258 1.236 -1.429 0.153
Schonleben F 1.244 0.235 6.576 0.257 0.797
Singhi AD 0.667 0.137 3.237 -0.503 0.615
Wu J 0.292 0.116 0.738 -2.602 0.009
0.626 0.408 0.961 -2.140 0.032
0.01 0.1 1 10 100
others high grade
Fig. 6 Forest plot of odds ratios with corresponding 95 % confidence intervals for the association of KRAS mutation with high‑grade dysplasia of 
IPMN
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type IPMNs rarely develops into invasive adenocarcino-
mas. When gastric type IPMNs progress to adenocar-
cinomas, it is the tubular type (Klöppel et al. 2014). The 
IPMNs with colloid adenocarcinoma is known to have 
a better prognosis than those with tubular adenocarci-
noma (Klöppel et al. 2014; Tan et al. 2015). Colloid ade-
nocarcinomas arising from IPMNs were associated with 
a high frequency of GNAS mutation (Tan et al. 2015). In 
agreement with the previous study (Tan et al. 2015), our 
results suggest that KRAS and GNAS mutational pattern 
may represent different pathways in the IPMN-adenocar-
cinoma sequence.
The GNAS gene encodes the α-subunit of the stimula-
tory G-protein (Gαs). Somatic activating GNAS muta-
tion results in an elevated level of cyclic adenosine 
monophosphate (cAMP) and in uncontrolled growth sig-
nalling (Landis et al. 1989; Weinstein et al. 2004). GNAS 
mutation has been found in various tumours, fibrous 
dysplasia, and McCune-Albright syndrome (Landis et al. 
1989; Weinstein et  al. 2004). Interestingly, most of the 
GNAS mutations at codon 201 in IPMNs result in either 
an R201H or an R201C substitution, which are the same 
mutation as in endocrine neoplasms (Landis et al. 1989; 
Weinstein et al. 2004). The endocrine tumours with acti-
vating GNAS mutations have been supposed to be associ-
ated with hormonal secretion.
Recently, inactivating nonsense mutations of RNF43 
gene that encodes a protein with E3 ubiquitin ligase 
activity were found in IPMNs (Amato et  al. 2014; 
Macgregor-Das and Iacobuzio-Donahue 2013; Sakamoto 
et al. 2015; Tan et al. 2015; Wu et al. 2011a). Our meta-
analysis found that RNF43 mutation was not associated 
with clinicopathologic parameters of patients with IPMN 
(Additional file 6: Table S4). Due to the lack of published 
articles, further studies need to clarify the roles and char-
acteristics of RNF43 mutation in IPMN patients.
This meta-analysis revealed that KRAS and GNAS 
mutations are not associated with the malignant poten-
tial or prognosis in patients with IPMN. This meta-anal-
ysis showed that frequency of KRAS mutation was rather 
lower in high-grade dysplasia than low- and/or interme-
diate-grade dysplasia. However, further more studies are 
needed to confirm the results. The frequency of GNAS 
mutation in IPMN patients did not differ among the 
three grades of dysplasia and in the absence or presence 
of associated adenocarcinoma. The association between 
GNAS mutation and the prognosis of patients with IPMN 
has been the subject of considerable controversy. GNAS 
mutation was significantly associated with high-grade 
dysplasia (Wu et al. 2011b), whereas wild-type GNAS in 
IPMNs was significantly related to the development of 
adenocarcinoma (Ideno et  al. 2015). However, as with 
this meta-analysis, other studies failed to show significant 
relationships between GNAS mutation, dysplasia grades, 
and the presence of adenocarcinoma (Amato et al. 2014; 
Hosoda et al. 2015; Kuboki et al. 2015; Singhi et al. 2014).
It has been well known that pancreatic cancers are 
more frequent in Ashkenazi Jews and African groups. 
However, the frequency of IPMN between races has not 
been known because of its rare incidence. Therefore, we 
simply classified IPMN patients into the Caucasian and 
Asian groups in this study, although the genetic changes 
of diverse and detailed ethnicity would be an interesting 
issue and broaden the novel biological pathway of IPMN.
The present meta-analysis has some limitations. First, 
the possibility of publication bias could not be completely 
excluded. Second, the individual study used in this meta-
analysis was done with relatively small sample sizes, due 
to the rare occurrence of IPMNs. Lastly, the different 
studies did not only use different methods for mutation 
detection but also different tumour materials, such as 
cystic fluid versus tissue specimen. This might confound 
the mutation detection rates.
In summary, this meta-analysis provides sensitive and 
specific diagnostic roles of KRAS and GNAS mutations 
for detecting the IPMN among the pancreatic cystic 
lesions. Furthermore, KRAS and GNAS mutations hint a 
possibility that patients with IPMN have which form of 
microscopic subtype.
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